AzTrials
AzTrials

Nasopharyngeal CarcinomaNCT00155181

Molecular Mechanism of Nasopharyngeal Carcinoma

An observational study of Nasopharyngeal Carcinoma, run by National Taiwan University Hospital at 1 site in Taiwan.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

EBV, infection process, immortalization, B lymphocytes, Epithelial cells, co-culture Epstein-Barr virus (EBV) belongs to human γ-herpes viruses. Unlike other human herpes viruses, EBV can only predominately infect two types of human cells: lymphoid cells and epithelial cells and its infection is associated with… Read more about this study

Who is it for?
Ages 30 to 65 years
Conditions the study is for
Nasopharyngeal Carcinoma
How many people
25 participants
Where
1 siteTaiwan
Study dates
Jan 2005to Aug 2005
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • diagnosis of nasopharyngeal carcinoma

Who cannot join

  • -

Trial locations and contacts

1 site in 1 country.

Taiwan1 site, 1 recruiting
  • National Taiwan University College of Medicine

    Taipei, 100

    Te-Huei Yeh, MD, Ph D, 886-2-23123456 ext. 5223, yth@ha.mc.ntu.edu.tw

    Ching-Hwa Tsai, pH.D

    Recruiting

Other trials in Taiwan

About this study

Official title: the Garduate Institute of Microbiology in National Taiwan University

EBV, infection process, immortalization, B lymphocytes, Epithelial cells, co-culture Epstein-Barr virus (EBV) belongs to human γ-herpes viruses. Unlike other human herpes viruses, EBV can only predominately infect two types of human cells: lymphoid cells and epithelial cells and its infection is associated with several human malignancies of these two cell types. The lymphoid cancers associated with EBV infection include Burkitt's lymphoma, Hodgkin's disease, B lymphoma in immunodeficient patients and T/NK cell lymphoma. The carcinomas associated with EBV are nasopharyngeal carcinoma and gastric carcinoma. One unique biological feature of EBV is that it can infect and immortalize primary B lymphocytes in vitro into lymphoblastoid cell lines (LCL). So far, limited information is known about the whole EBV infection process and its regulation mechanism for immortalization. In this project, three EBV infection models are setting up to reveal the cellular events and signal transduction pathway possibly involved in EBV infection process and immortalization course of action.

Read the detailed description

Nasopharyngeal carcinoma (NPC), a human malignancy derived from the nasopharyngeal epithelial cells, is occurring highly frequently in Taiwan. Of note, the average ages of NPC individuals are usually ten years younger than those of patients with other head and neck cancers. Clinically, this early onset and high incidence of metastasis in NPC may contribute to its poor prognosis. Fortunately, NPC is usually radio-and chemo-therapy sensitive during the early stage. So, the more we understand NPC pathogenesis, the more efficient detection methods would be developed for NPC early diagnosis and prognosis.

Four unique characteristics have been reported for NPC: geographic preference, heavy infiltration of lymphocytes, high incidence of metastasis and association with Epstein-Barr virus (EBV). According to our hypothesis that both cellular changes and viral factors are crucial for NPC development, four major long-term study goals have been carried out in our lab: (1) identification and characterization of the cellular and viral factors that are involved in NPC formation, (2) elucidation of potencies of these molecules as clinical diagnosis and prognosis markers of NPC, (3) investigation of the molecular and biological linkage between EBV infection and NPC development and (4) establishment of a drug-screening system for NPC chemotherapy.

Based on our assumption that both cellular genes and viral factors are involved in NPC carcinogenesis, the following genes are chosen as the major study targets in this five-year grant. Firstly, to asses the alteration of cellular gene expression, we choose three cytokine genes 【interleukin (IL)-1, IL-7 and IL-13】, three inhibitors of apoptosis proteins (IAP) genes (survivin, HIAP-1, and HIAP-2), two specific cellular genes (osteoblast-specific factor-2 and polymeric immunoglobulin receptor) and one tumor suppressor gene (tumor susceptibility gene TSG101) in our proposal. All these genes exhibit special expression profiles in NPC biopsies in our preliminary study. So, the regulation and effect of these genes in epithelial cells would be the study focus. Secondly, two EBV viral genes, Zta and LMP2A, the former encoded immediately early lytic product and the later encoded latent membrane protein, are selected for this study. In our previous grant, we found that Zta can up-regulate TKT (trk-related tyrosine kinase) and matrix metalloproteinases (MMP)-1 which is a down-stream effector of TKT. Therefore we will extend the study on how Zta and LMP2A regulate and influence anti-apoptotic network and metastasis progression. Based on our preliminary data, this proposal is highly approachable and the results may provide valuable information for NPC diagnosis, prognosis and treatment.

Keywords
Epstein-Barr virus, Nasopharyngeal carcinoma, Carcinogenesis
Medical subject headings
Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections, Carcinogenesis

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Sep 2005 (estimated)
  2. Study startJan 2005
  3. Study completionAug 2005

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Other
Enrolment
25 participants
IDs, dates and publications
ClinicalTrials.gov ID
NCT00155181
Sponsor's protocol ID
9361700387
Other IDs
NHRI-EX94-9419BI
Status last verified
Jan 2005
First submitted
9 Sep 2005
Last updated
12 Sep 2005
Results posted
No

Questions about this trial

What is this clinical trial studying?

An observational study of Nasopharyngeal Carcinoma, run by National Taiwan University Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 12 Sep 2005. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ching-Hwa Tsai, Ph D (886-2-23123456 ext. 8298, chtsai@ha.mc.ntu.edu.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Sep 2005.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in